| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label … CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, ... The lancet oncology 19 (2), 216-228, 2018 | 694 | 2018 |
| Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study AH Wei, SA Strickland Jr, JZ Hou, W Fiedler, TL Lin, RB Walter, A Enjeti, ... Journal of Clinical Oncology 37 (15), 1277-1284, 2019 | 635 | 2019 |
| Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma S Kumar, JL Kaufman, C Gasparetto, J Mikhael, R Vij, B Pegourie, ... Blood, The Journal of the American Society of Hematology 130 (22), 2401-2409, 2017 | 511 | 2017 |
| Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study JF Seymour, S Ma, DM Brander, MY Choi, J Barrientos, MS Davids, ... The Lancet Oncology 18 (2), 230-240, 2017 | 380 | 2017 |
| Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments SK Agarwal, CD DiNardo, J Potluri, M Dunbar, HM Kantarjian, ... Clinical Therapeutics 39 (2), 359-367, 2017 | 180 | 2017 |
| Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy S Coutre, M Choi, RR Furman, H Eradat, L Heffner, JA Jones, B Chyla, ... Blood, The Journal of the American Society of Hematology 131 (15), 1704-1711, 2018 | 165 | 2018 |
| Pharmacokinetics of venetoclax, a novel BCL‐2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non‐Hodgkin lymphoma AH Salem, SK Agarwal, M Dunbar, SLH Enschede, RA Humerickhouse, ... The Journal of Clinical Pharmacology 57 (4), 484-492, 2017 | 109 | 2017 |
| Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). F Ravandi, RB Walter, M Subklewe, V Buecklein, M Jongen-Lavrencic, ... Journal of Clinical Oncology 38 (15_suppl), 7508-7508, 2020 | 92 | 2020 |
| Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma SK Agarwal, AH Salem, AV Danilov, B Hu, S Puvvada, M Gutierrez, ... British journal of clinical pharmacology 83 (4), 846-854, 2017 | 87 | 2017 |
| Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor: results of a single‐and multiple‐dose study SK Agarwal, B Hu, D Chien, SL Wong, AH Salem The Journal of Clinical Pharmacology 56 (11), 1335-1343, 2016 | 83 | 2016 |
| Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis AK Jones, KJ Freise, SK Agarwal, RA Humerickhouse, SL Wong, ... The AAPS journal 18, 1192-1202, 2016 | 82 | 2016 |
| Statins enhance efficacy of venetoclax in blood cancers JS Lee, A Roberts, D Juarez, TTT Vo, S Bhatt, L Herzog, S Mallya, ... Science translational medicine 10 (445), eaaq1240, 2018 | 80 | 2018 |
| A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, in relapsed/refractory acute myeloid leukemia (R/R AML) F Ravandi, AS Stein, HM Kantarjian, RB Walter, P Paschka, ... Blood 132, 25, 2018 | 77 | 2018 |
| Effect of low‐and high‐fat meals on the pharmacokinetics of venetoclax, a selective first‐in‐class BCL‐2 inhibitor AH Salem, SK Agarwal, M Dunbar, S Nuthalapati, D Chien, KJ Freise, ... The Journal of Clinical Pharmacology 56 (11), 1355-1361, 2016 | 77 | 2016 |
| A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers SK Agarwal, RL Kriel, RC Brundage, VD Ivaturi, JC Cloyd Epilepsy research 105 (3), 362-367, 2013 | 77 | 2013 |
| Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study S de Vos, LJ Swinnen, D Wang, E Reid, N Fowler, J Cordero, M Dunbar, ... Annals of Oncology 29 (9), 1932-1938, 2018 | 70 | 2018 |
| Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33/CD3 BiTE®(bispecific T-cell engager) in patients with relapsed … M Subklewe, A Stein, RB Walter, R Bhatia, AH Wei, D Ritchie, V Bücklein, ... Blood 134, 833, 2019 | 69 | 2019 |
| A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are≥ to 65 … C DiNardo, D Pollyea, K Pratz, MJ Thirman, A Letai, M Frattini, B Jonas, ... Blood 126 (23), 327, 2015 | 67 | 2015 |
| Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged≥ 65 years with acute myeloid leukemia A Wei, SA Strickland, GJ Roboz, JZ Hou, W Fiedler, TL Lin, G Martinelli, ... Blood 128 (22), 102, 2016 | 65 | 2016 |
| Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites H Liu, MJ Michmerhuizen, Y Lao, K Wan, AH Salem, J Sawicki, M Serby, ... Drug Metabolism and Disposition 45 (3), 294-305, 2017 | 62 | 2017 |
